Biopharmaceutical company AstraZeneca plc (STO:AZN) (LON:AZN) (Nasdaq:AZN) announced on Monday that its Tagrisso (osimertinib), when combined with chemotherapy, has demonstrated a significant and clinically meaningful improvement in progression-free survival (PFS), compared to Tagrisso alone, in patients with locally advanced (Stage IIIB-IIIC) or metastatic (Stage IV) epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC).
These findings were presented during a Presidential Symposium at the International Association for the Study of Lung Cancer (IASLC) 2023 World Conference on Lung Cancer (WCLC).
The combination therapy reduced the risk of disease progression or death by 38% in comparison to Tagrisso monotherapy. By investigator assessment, the combination extended median PFS by 8.8 months versus Tagrisso alone. Blinded independent central review (BICR) results further supported this outcome, with Tagrisso plus chemotherapy extending median PFS by 9.5 months. Significantly, this PFS benefit was observed across all pre-specified subgroups, including sex, race, EGFR mutation type, age at diagnosis, smoking history and baseline central nervous system (CNS) metastasis status.
While overall survival (OS) data were not fully mature at the time of analysis, a favourable trend was noted for Tagrisso plus chemotherapy.
Lipocine doses first cohort in LPCN 1154 study
BenevolentAI reports positive Phase Ia safety and pharmacokinetic data for BEN-8744
AstraZeneca announces US approval for Ultomiris for NMOSD treatment
GenSight Biologics declares efficacy and safety of LUMEVOQ four years post-injection
Nuvalent's NVL-520 receives FDA breakthrough therapy designation
Nuvalent commences NVL-655 phase 2 clinical trial in subjects with NSCLC and other solid tumours
GC Biopharma's GC1130A receives EMA Orphan Drug Designation
Guangzhou Fermion Technology's FZ008-145 IND application receives Chinese regulatory approval
Vistagen granted European patent for AV-101 to treat neuropathic pain
GenSight Biologics reports business and financial update
Alora Pharmaceuticals announces Relexxii commercial launch
IGC Pharma granted patent for Alzheimer's drug formulation
NRx Pharmaceuticals signs data agreement with Columbia University for IV Ketamine trials